CagriSema: Risks & Legal Status
Important safety information, risks, and regulatory status
📌TL;DR
- •5 risk categories identified
- •0 high-severity risks
- •Legal status varies by country (4 countries listed)
Risk Assessment
CagriSema is not yet FDA-approved. NDA was filed in 2025 and is under regulatory review. The full safety profile continues to be established.
The semaglutide component is associated with thyroid C-cell tumors in rodent studies. CagriSema is expected to carry a boxed warning. Contraindicated in patients with MTC or MEN2 history.
GI adverse events occurred in 79.6% of CagriSema patients in REDEFINE 1 (vs 39.9% placebo). The dual amylin/GLP-1 mechanism produces additive GI effects. Dehydration from GI events may cause complications.
Both GLP-1 agonists and amylin analogs have been associated with pancreatitis. Patients should report persistent severe abdominal pain.
The substantial weight loss (20.4%) increases cholelithiasis and cholecystitis risk consistent with rapid weight loss from any cause.
⚠️Important Warnings
- •INVESTIGATIONAL AGENT: CagriSema is not approved by any regulatory authority. NDA filed with FDA in 2025 for weight management.
- •EXPECTED BOXED WARNING: The semaglutide component is expected to carry a thyroid C-cell tumor boxed warning. Do not use in patients with MTC or MEN2 history.
- •GI adverse events are very common (79.6% in REDEFINE 1). Dual amylin/GLP-1 mechanism produces additive gastrointestinal effects. Maintain hydration.
- •Do not use during pregnancy. Both components should be discontinued before planned conception.
- •No cardiovascular outcomes data are available for the combination.
Legal Status by Country
| Country | Status | Notes |
|---|---|---|
| United States | Investigational | NDA filed in 2025 for chronic weight management. Under FDA review. Expected regulatory decision in 2026. |
| European Union | Investigational | Regulatory submission expected as part of global filing strategy. |
| United Kingdom | Investigational | Not MHRA-approved. Regulatory pathway being pursued. |
| Canada | Investigational | Not Health Canada-approved. Regulatory submissions as part of global filing strategy. |
Community Risk Discussions
See how the community discusses and manages these risks in practice.
Based on 15+ community reports
View community protocolsCritical Safety Information#
CagriSema is an investigational combination medication with an NDA filed but not yet approved. The safety profile is derived from the Phase 3 REDEFINE program enrolling over 4,600 participants. As a combination product, CagriSema carries the risk profiles of both its components.
Investigational Status#
CagriSema's NDA was filed with the FDA in 2025 following the REDEFINE Phase 3 results. A regulatory decision is expected in 2026. Until approval, CagriSema should only be used within clinical trials.
Dual-Mechanism Risk Profile#
CagriSema's combination of amylin and GLP-1 receptor agonism produces additive gastrointestinal effects. The 79.6% GI adverse event rate in REDEFINE 1 is higher than what is typically observed with semaglutide alone (~44-60% for GI events), reflecting the additive impact of amylin-mediated gastric emptying delay on top of GLP-1 receptor agonism.
GLP-1 Agonist Class Risks#
Thyroid C-Cell Tumors#
The semaglutide component of CagriSema carries the GLP-1 agonist class boxed warning. CagriSema is expected to be contraindicated in patients with personal or family history of MTC or MEN2.
Pancreatitis#
Both GLP-1 agonists and amylin analogs carry pancreatitis risk. The combined use may warrant enhanced vigilance.
Gallbladder Disease#
With 20.4% mean weight loss, CagriSema produces substantial rapid weight change that increases gallstone risk.
Acute Kidney Injury#
Dehydration from the higher rate of GI adverse events may increase AKI risk.
Amylin Agonist-Specific Risks#
Injection Site Reactions#
Amylin analogs (including pramlintide) have been associated with injection site reactions. CagriSema may have slightly higher injection site reaction rates than semaglutide alone.
Hypoglycemia in Combination with Insulin#
The cagrilintide component suppresses glucagon and delays gastric emptying, which in combination with insulin therapy may increase hypoglycemia risk.
Regulatory and Legal Status#
| Jurisdiction | Status | Notes |
|---|---|---|
| United States (FDA) | NDA filed | Under review; expected decision 2026 |
| European Union (EMA) | Regulatory submission pending | Global filing strategy |
| United Kingdom (MHRA) | Not yet submitted | Under consideration |
| Canada (Health Canada) | Not yet submitted | Under consideration |
At-Risk Populations#
Patients with MTC or MEN2 History#
Expected absolute contraindication due to semaglutide component.
Pregnant and Breastfeeding Women#
Both components carry pregnancy risks. Discontinue before planned conception with appropriate washout period (both components have approximately 7-day half-lives).
Patients with Severe GI Disease#
The additive gastric emptying effects from dual amylin/GLP-1 activation may be poorly tolerated by patients with pre-existing gastroparesis or GI motility disorders.
Patients on Insulin#
The combination of amylin and GLP-1 agonism with insulin requires careful dose management to minimize hypoglycemia risk.
Risk Mitigation#
- Use only within clinical trials until regulatory approval
- Screen for MTC/MEN2 history
- Follow dose escalation schedule to minimize GI adverse events
- Maintain adequate hydration
- Monitor for pancreatitis and gallbladder symptoms
- Adjust insulin doses when initiating CagriSema in T2D patients
Related Reading#
Frequently Asked Questions About CagriSema
Explore Further
Medical Disclaimer
This website is for educational and informational purposes only. The information provided is not intended to diagnose, treat, cure, or prevent any disease. Always consult with a qualified healthcare professional before using any peptide or supplement.